TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Frequency of adverse events (AE) grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical respiratory effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of psychosocial telephone counseling intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: rate of actionable mutations identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatiotemporal measures of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition measurements (body weight, body mass, waist and hip circumferences)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conformity of self-diagnosis and medical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of Ketamine on Suicidality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic exposure parameters of lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline on assessment instrument
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint range of motion measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitic count in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence and Frequency of Myoclonus
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testosterone levels in blood and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients with failed disease based on changes in cathepsin G levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Participants with Rituximab Related Grade 3 or higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in loaded knee pain (single leg squat) visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee function measured by the TAS questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee function measured by the IKDC questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee function measured by the KOOS questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Post Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reaching Target Level of Intact Parathyroid Hormone (iPTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Any Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Diaphragmatic amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area under curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practicality of performing the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient tolerance of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timeliness of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: # of needle adjustments required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of overall KOOS or FOAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero up to time (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Median motor and sensory distal latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in self-reported symptoms and functionality scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain assessment using Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion size assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (area under the curve) 0-t of misoprostol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (area under the curve) 0-inf of misoprostol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pacing system-, MRI- and implant procedure-related complication-free rate
Endpoint domain: Adverse events/effects
Primary endpoint: atrial and ventricular lead-related complication-free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Antitumoral Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient global impression of improvement score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: insulin/glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum distance walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnostic ability of clinical indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loteprednol etabonate concentrations in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saturation level measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in degree of Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Discontinuation Due to Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Drug-Related Problems
Endpoint domain: Adverse events/effects
Primary endpoint: mortality of CAP patients
Endpoint domain: Mortality/survival
Primary endpoint: Change in infiltrate thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration to full recovery (able to do all activities)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in German Cockroach-Specific Serum IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom From Recurrence of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HOXA 10 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Proliferation Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of ctDNA for detection of metastatic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of ctDNA for detection of metastatic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: health outcomes after treatment end
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Digit Span Test Total Score at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hematological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients receiving surveillance colonoscopy recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Volumetric measurement of the pancreas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited Local and Systemic Reactions After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: AUCτ,ss of Amlodipine and Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of Amlodipine and Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in metabolomic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EEG power in alpha band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral activation in fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent adverse experiences (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Circulating Tumor Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain measured by VISA-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year Disease-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: sRAGE levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality after Acute Kidney Injury
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of AKI-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Distribution of risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: in-breast recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Reproducibility of delivering preoperative APBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Isokinetic Leg Extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal Upper and Lower Body Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PA spine BMD over 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PA spine BMD over 2nd year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safe serum levels of lidocaine infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central retinal/lesion thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: hospitalization due to heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Time-weighted Average of Glucose (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Maximum Ambient Glucose Concentration (Gmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Beta Cell Sensitivity to Glucose (Φ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to clinical stability-respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Corneal Curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Lower Limb Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anatomy of treated vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alterations in inflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Consumption of propofol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Haemoglobin concentration relative to baseline value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prognosis of patients
Endpoint domain: Mortality/survival
Primary endpoint: CMV-DNA load in aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratinized Mucosa Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of X-ray Images
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of DTS images
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of CT (or MRI) images
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of olaparib in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum-tolerated dose of olaparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Toxicity profile and dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibition of Platelet Aggregation (IPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EEG relative power in the delta band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG relative power in the theta band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG relative power in the alpha band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG relative power in the beta band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG relative power in the gamma band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: COP trajectory recorded from the force plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle sialylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily plasma glucose excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean plasma glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-relapse Mortality (NRM)
Endpoint domain: Mortality/survival
Primary endpoint: Patient reported comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Delta CFU/ml/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Positive Symptom Item Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity Difference (SPID) at 8-hours (SPID8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Crizotinib
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Dose (CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma alpha-synuclein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC Nurr1 mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC phosphorylated and total levels of pSerine9 and t-glycogen synthase kinase-3B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma brain-derived neurotrophic factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC pThreonine308 and t-protein kinase B (Akt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Emergence Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of positive tests for drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Windows of drug detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Toxicities of ATO combined with radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of ATO combined with stereotactic radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reducing rate of HAMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-1Beta level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-6 level in GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pupil Size Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Greater Than or Equal to 6 Hours of Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Objective Structure Assessment of Technical Skill (OSATS) scores for passing a needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Objective Structure Assessment of Technical Skill (OSATS) scores for making a microsurgical tie
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in time required to pass a needle
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in time required to complete microsurgical tie
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite allergy disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall Pain Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biochemically Verified 7-day Point Prevalence Tobacco Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight Change at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Endothelial Progenitor Cells per mm^2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPD readings after Glucose/Galactose infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary amphetamine positive rates
Endpoint domain: Adverse events/effects
Primary endpoint: Periimplant marginal recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants having subjective symptoms after hysterectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Prematurely Discontinued the Treatment Due to Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Unanticipated Safety Issues
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Absolute Relative Difference for CGM and POC Glucose Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of CGM Instrument Issues
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage Change in Difference in Apparent Diffusion Coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Bleeding Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Possible or Definite Recurrent Clostridium Difficile Infection (CDI)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in clinical appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful haemostasis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Brief Pain Index (BPI) At Its Worst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attachment Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of detectable hair growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of corneal endothal number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Cell density rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Cell variation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Hexagonality rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pachymetry specular microscopy results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes